Wangroongsub Yongsak, Tanavalee Aree, Wilairatana Vajara, Ngarmukos Srihatach
Department of Orthopedic Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
J Med Assoc Thai. 2010 Jul;93(7):805-11.
Glucosamine sulfate has been recommended for treatment of knee osteoarthritis in several published guidelines. However, there are various preparations of glucosamine that may result in different pharmacokinetic and clinical outcomes.
Comparison of clinical outcomes of two different preparations of glucosamine sulfate (Sodium chloride salt and Potassium chloride salt) in patients with mild and moderate degree knee osteoarthritis. Laboratory tests to monitor drug safety were also studied.
Patients with symptomatic mild and moderate degree knee osteoarthritis were randomly assigned to receive treatment with either glucosamine sulfate with potassium salt (GS-K) 1500 mg daily or glucosamine sulfate with sodium salt (GS-Na) 1500 mg daily. Types of treatments were blinded to both patients and evaluators. Clinical assessments were done two weeks prior to initiation of treatment and then every four weeks until the sixteen week of treatment. Standing knee radiographs were taken at the initial visit. Patients with Ahlback stage 1 to 4 were included in the current study. Clinical data included range of motion, presence or absence of joint effusion, WOMAC and SF36. Laboratory studies were also done to evaluate drug safety, including BUN, creatinine, electrolytes, and liver function test. Adverse drug reactions were also recorded.
Ninety patients with mild and moderate knee osteoarthritis (Ahlback grade 1-4) were randomized to two treatment groups, forty-five patients each. Demographic data and initial clinical assessment were similar in both groups. Both groups demonstrated improvement of WOMAC score and SF-36 at final follow-up but this did not reach statistical significance. Differences of WOMAC score and SF-36 between the two groups were not significant at any follow-up visit. Serum potassium level increased more significantly in the GS-K group but did not exceed normal value.
In this short-term randomized comparison, glucosamine sulfate with potassium salt (GS-K) is as effective in pain relief and as safe as glucosamine sulfate with sodium salt (GS-Na) for treatment of mild and moderate degree knee osteoarthritis.
硫酸氨基葡萄糖已在多项已发表的指南中被推荐用于治疗膝关节骨关节炎。然而,氨基葡萄糖有多种制剂,这可能导致不同的药代动力学和临床结果。
比较两种不同制剂的硫酸氨基葡萄糖(氯化钠盐和氯化钾盐)在轻中度膝关节骨关节炎患者中的临床疗效。还研究了监测药物安全性的实验室检查。
有症状的轻中度膝关节骨关节炎患者被随机分配接受每日1500毫克的硫酸氨基葡萄糖钾盐(GS-K)或每日1500毫克的硫酸氨基葡萄糖钠盐(GS-Na)治疗。治疗类型对患者和评估者均保密。在治疗开始前两周进行临床评估,然后每四周进行一次评估,直至治疗的第16周。在初次就诊时拍摄站立位膝关节X线片。纳入Ahlback 1至4期的患者进行本研究。临床数据包括关节活动范围、关节积液的有无、WOMAC和SF36。还进行了实验室研究以评估药物安全性,包括血尿素氮、肌酐、电解质和肝功能检查。还记录了药物不良反应。
90例轻中度膝关节骨关节炎(Ahlback 1-4级)患者被随机分为两个治疗组,每组45例。两组的人口统计学数据和初始临床评估相似。两组在最终随访时WOMAC评分和SF-36均有改善,但未达到统计学意义。两组在任何随访时WOMAC评分和SF-36的差异均无统计学意义。GS-K组血清钾水平升高更显著,但未超过正常值。
在这项短期随机比较中,硫酸氨基葡萄糖钾盐(GS-K)在缓解疼痛方面与硫酸氨基葡萄糖钠盐(GS-Na)一样有效,且在治疗轻中度膝关节骨关节炎方面同样安全。